Federal contract award
75A50119C00007
VENATORX PHARMACEUTICALS, INC.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST SHARING |
| Obligations | $106.6M |
| Current contract value | $131.8M |
| Potential contract value / ceiling | $146.9M |
| Start date | Jul 17, 2019 |
| Current end date | Sep 30, 2025 |
| Potential end date | Sep 30, 2025 |
| Latest award activity | May 26, 2026 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 3 of 3 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| May 26, 2026 | P00030 | $-615.4K | THE PURPOSE OF THIS BILATERAL MODIFICATION DE-OBLIGATES CANCELING YEAR FUNDS FROM REQUISITION OS256610 IN THE AMOUNT OF (-$615,177.10) FROM CLIN0006 AND FROM REQUISITION OS257789 IN THE AMOUNT OF (-$222.20) FROM CLIN00001. |
| Sep 3, 2025 | P00029 | $-0 | THE PURPOSE OF THIS BILATERAL MODIFICATION DE-OBLIGATES FUNDS FROM REQUISITION OS237567 IN THE AMOUNT OF (-.01) FROM CLIN0001. |
| Nov 25, 2024 | P00028 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE ARTICLES I.1 FEDERAL ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES, 52.204-14 SERVICES CONTRACT REPORTING REQUIREMENTS. |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.